Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
SHUKRA PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SHUKRA PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
SHUKRA PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 89 | 321 | - | |
Low | Rs | 11 | 232 | - | |
Sales per share (Unadj.) | Rs | 53.7 | 95.5 | - | |
Earnings per share (Unadj.) | Rs | 4.0 | -24.1 | - | |
Cash flow per share (Unadj.) | Rs | 5.7 | -20.0 | - | |
Dividends per share (Unadj.) | Rs | 0.50 | 0 | - | |
Avg Dividend yield | % | 1.0 | 0 | - | |
Book value per share (Unadj.) | Rs | 23.1 | 75.0 | - | |
Shares outstanding (eoy) | m | 10.96 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.9 | 2.9 | 32.1% | |
Avg P/E ratio | x | 12.4 | -11.5 | -108.1% | |
P/CF ratio (eoy) | x | 8.8 | -13.9 | -63.2% | |
Price / Book Value ratio | x | 2.2 | 3.7 | 58.7% | |
Dividend payout | % | 12.4 | 0 | - | |
Avg Mkt Cap | Rs m | 547 | 46,656 | 1.2% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 44 | 2,928 | 1.5% | |
Avg. sales/employee | Rs Th | 0 | 3,756.2 | - | |
Avg. wages/employee | Rs Th | 0 | 682.1 | - | |
Avg. net profit/employee | Rs Th | 0 | -946.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 588 | 16,125 | 3.6% | |
Other income | Rs m | 12 | 113 | 10.6% | |
Total revenues | Rs m | 600 | 16,238 | 3.7% | |
Gross profit | Rs m | 54 | -2,794 | -1.9% | |
Depreciation | Rs m | 18 | 696 | 2.6% | |
Interest | Rs m | 3 | 437 | 0.6% | |
Profit before tax | Rs m | 44 | -3,814 | -1.2% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 238 | 0.1% | |
Profit after tax | Rs m | 44 | -4,063 | -1.1% | |
Gross profit margin | % | 9.1 | -17.3 | -52.6% | |
Effective tax rate | % | 0.8 | -6.2 | -12.7% | |
Net profit margin | % | 7.5 | -25.2 | -29.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 531 | 11,810 | 4.5% | |
Current liabilities | Rs m | 425 | 6,645 | 6.4% | |
Net working cap to sales | % | 18.0 | 32.0 | 56.1% | |
Current ratio | x | 1.2 | 1.8 | 70.3% | |
Inventory Days | Days | 0 | 111 | 0.0% | |
Debtors Days | Days | 1,873 | 124 | 1,511.0% | |
Net fixed assets | Rs m | 219 | 6,884 | 3.2% | |
Share capital | Rs m | 39 | 75 | 52.3% | |
Net worth | Rs m | 253 | 12,657 | 2.0% | |
Long term debt | Rs m | 38 | 4,448 | 0.8% | |
Total assets | Rs m | 750 | 23,909 | 3.1% | |
Interest coverage | x | 16.8 | -7.7 | -217.4% | |
Debt to equity ratio | x | 0.1 | 0.4 | 42.4% | |
Sales to assets ratio | x | 0.8 | 0.7 | 116.4% | |
Return on assets | % | 6.3 | -15.2 | -41.2% | |
Return on equity | % | 17.4 | -32.1 | -54.3% | |
Return on capital | % | 16.2 | -19.8 | -82.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 32 | 1,376 | 2.3% | |
From Investments | Rs m | -44 | -423 | 10.5% | |
From Financial Activity | Rs m | 49 | 4,037 | 1.2% | |
Net Cashflow | Rs m | 37 | 4,990 | 0.7% |
Compare SHUKRA PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare SHUKRA PHARMA With: BLISS GVS PHARMA ZIM LABORATORIES ZENOTECH LABS AMBALAL SARABHAI HEMO ORGANIC
Asian stocks inched higher on Tuesday as investors awaited a slew of economic data, corporate earnings and the U.S. Federal Reserve's policy meeting.